US and Swiss laboratory Roche pointed out that their treatment can reduce the risk of Covid-19 symptomatic infection by 81%
American laboratory Regenerating element With his Swiss partner Roche Monday revealed the new results of a promising clinical cocktail trial designed to reduce the risk of diabetes. COVID-19 infection In a sick family.
The American laboratory pointed out in a press release that the Phase 3 clinical trial, which corresponds to the most advanced stage of clinical research, aims to evaluate the association between casirivimab and imdevimab in the families of infected persons, thus achieving its main goal.
At the beginning of the trial, administered by subcutaneous injection at a dose of 1200 mg, the treatment reduced the risk of symptomatic infection in uncontaminated patients by 81%.
The team explained that despite this, those who still showed symptoms of COVID-19 infection saw them disappear faster, compared to three weeks for patients who received a placebo. Roche In another statement, they also presented the results of these trials.
These clinical trials are designed to evaluate Uninfected patients, They have no antibodies or symptoms, and live in one person’s family, and one person has been diagnosed positive in the past four days. They were made on samples of 1505 people.
The two groups will promptly submit the results of these trials to the health authorities.